These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 28956258)

  • 21. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia.
    Ginsberg HN
    J Clin Endocrinol Metab; 2006 Feb; 91(2):383-92. PubMed ID: 16291700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological management of diabetic dyslipidemia.
    Filippatos TD; Florentin M; Georgoula M; Elisaf MS
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):187-200. PubMed ID: 27868450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
    Aguiar C; Alegria E; Bonadonna RC; Catapano AL; Cosentino F; Elisaf M; Farnier M; Ferrières J; Filardi PP; Hancu N; Kayikcioglu M; Mello E Silva A; Millan J; Reiner Ž; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Zamorano JL; Ferrari R
    Atheroscler Suppl; 2015 Sep; 19():1-12. PubMed ID: 26315511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes.
    Standl E
    Diab Vasc Dis Res; 2013 Mar; 10(2):99-114. PubMed ID: 22718811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy.
    Gaudet D; Drouin-Chartier JP; Couture P
    Can J Cardiol; 2017 Jul; 33(7):872-882. PubMed ID: 28365054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New insights into the pathophysiology of dyslipidemia in type 2 diabetes.
    Taskinen MR; Borén J
    Atherosclerosis; 2015 Apr; 239(2):483-95. PubMed ID: 25706066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role for combination therapy in diabetic dyslipidemia.
    Warraich HJ; Wong ND; Rana JS
    Curr Cardiol Rep; 2015 May; 17(5):32. PubMed ID: 25894802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Statins and kidney disease].
    Bigazzi R; Grimaldi D; Bianchi S
    G Ital Nefrol; 2012; 29(2):160-73. PubMed ID: 22538946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [How to treat dyslipidemia in patients with metabolic syndrome].
    Soška V
    Vnitr Lek; 2015; 61(7-8):721-4. PubMed ID: 26375703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diabetic Dyslipidemia].
    Merkel M
    Dtsch Med Wochenschr; 2021 Jan; 146(2):85-91. PubMed ID: 33465804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus.
    Wanner C; Krane V
    Kidney Blood Press Res; 2011; 34(4):209-17. PubMed ID: 21691123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lipids-Diagnosis and therapy in diabetes mellitus (Update 2019)].
    Wascher TC; Paulweber B; Toplak H; Saely CH; Drexel H; Föger B; Hoppichler F; Stulnig T; Stingl H; Clodi M;
    Wien Klin Wochenschr; 2019 May; 131(Suppl 1):136-138. PubMed ID: 30980157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Multimodal therapy of dyslipidemia].
    Stahn A; Hanefeld M
    Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of diabetic dyslipoproteinemia.
    Steinmetz A
    Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):239-45. PubMed ID: 12951627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dyslipemia in diabetics treated with statins. Results of the DYSIS study in Spian].
    Millán J; Alegría E; Guijarro C; Lozano JV; Vitale GC; González-Timón B; González-Juanatey JR
    Med Clin (Barc); 2013 Nov; 141(10):430-6. PubMed ID: 23246165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
    Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
    Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.